CXCL8 and neoplasm: G31P is a synthetic form of CXCL8 with modifications in lysine to arginine (K11R) and glycine to proline (G31P) substitutions, which confer potent CXCR1/2 antagonism, thereby blocking ELR+ CXC chemokines signaling pathways involved in tumor growth, neutrophil infiltration, and resistance to therapy [20,28].